Print — Cathy McCartney
Teva Is a Hold
Granix® Hematopoietic Agent TBO-Filgrastim, Preservative Free 480 mcg / 0.8 mL Subcutaneous Injection Prefilled Syringe 5 Syringes
Teva Pharmaceuticals - pdf download
NDC 63459-910 Granix Tbo-filgrastim
Resources & Support from Teva CORE | GRANIX
FDA approves new indication, vial presentation for Teva's Granix | Drug Store News
A Look at Teva's Dominance in the Biosimilar Space
Legal Notice | GRANIX® (tbo-filgrastim) injection
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
15_03.jpg
New Drug Product: GRANIX - MPR
Rx Item-Granix 300MCG 10X1 ML Single Dose Vial -Keep Refrige
US Pharmacist January 2016
Tbo-filgrastim Approved for Chemotherapy-Induced Neutropenia - MPR
NDC 63459-910 Granix Tbo-filgrastim
TEVA PHARMACEUTICALS USA, INC: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Teva bolsters its biosimilar business through $160m Celltrion deal
Granix - FDA prescribing information, side effects and uses
63459091236 - Henry Schein Medical
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
ACTAVIS: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
BUY tbo-filgrastim (GRANIX) 300 ug/.5mL Cephalon, Inc.
Granix by Teva Pharmaceuticals, Inc
Teva's Granix Gets FDA Approval for Expanded Indication
In Focus: Making the case for biosimilars - MM+M - Medical Marketing and Media
Teva bolsters its biosimilar business through $160m Celltrion deal
